Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer

Published:1997-12 Issue:11 Volume:76 Page:1494-1499
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ando M,Eguchi K,Shinkai T,Tamura T,Ohe Y,Yamamoto N,Kurata T,Kasai T,Ohmatsu H,Kubota K,Sekine I,Hojo N,Matsumoto T,Kodama T,Kakinuma R,Nishiwaki Y,Saijo N

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc1997584.pdf

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group;Japanese Journal of Clinical Oncology;2020-03-02

2. The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: a general template for research on TCMs;Scientific Reports;2017-03-23

3. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts;Neuro-Oncology;2007-10-01

4. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944;Anti-Cancer Drugs;2007-02

5. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts1;Neuro-Oncology;2007-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP